FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes

Once-weekly dulaglutide was approved based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin.